Yükleniyor... / Loading...
This observational study investigated the genetic features (homologous recombination status) of tumor tissue samples in patients diagnosed with ovarian cancer. It enrolled patients aged 20 and older who had a clinical diagnosis of ovarian cancer before surgery and could provide a tissue sample. It was conducted as a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Patients who can approve informed consent and sign it. Patients who show their will to participate in this study and can sign the informed consent forms by themselves. 2. Patients who are clinically diagnosed as having ovarian cancer and can provide written informed consent before the surgery. 3. Patients who can provide tumor tissue specimens. (except ascites cytology and cell block specimens) 4. Patients who are 20 years old and over at the enrollment. 5. Patients with ECOG Performance status (PS): 0-2. Exclusion Criteria: 1. Patients with active concomitant malignancy\* except breast cancer. \*Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma. 2. Patients who are diagnosed as any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll this study because of safety reasons or any influence to study outcomes. 3. Any other cases that are inappropriate to enroll this study, judged by study principal investigator.